PharmGKB Policies

If you cannot find the information that you are looking for, you can request assistance from the PharmGKB team.

PharmGKB Data Usage Agreement

PharmGKB grants use of its contents for research purposes. The use of this data and knowledge is NOT available for redistribution. The PharmGKB is a NIH NIGMS sponsored research project (GM61374) funded to collect, encode, and disseminate knowledge about the impact of human genetic variations on drug response. The knowledge and data covered by this agreement include and are not limited to research variant annotations from the literature, clinical interpretations of these variants, gene summaries for very important pharmacogenes (VIPs), pathway and network diagrams, relationships between gene, drugs and diseases and all software that support the PharmGKB. This content is freely available to researchers in academia and industry for RESEARCH PURPOSES. Absent the issuance of a license by Stanford, the content shall not be used in any non-research commercial application in any form. If you are interested in using any contents from the PharmGKB for a product or with a plan to redistribute (e.g., a website), then you must obtain a separate license. Please contact Dr. Teri Klein if you require further information.

Terms and Conditions of Use

The PharmGKB is for research purposes. Prior to initiating research with this data as the researcher, you are obligated to know the requirements of HIPAA policy and be aware of other applicable privacy laws. Because this database may fall under HIPAA regulations, we must track all access to and use of the database. Specifically, we must and are able to determine what pieces of data you are accessing, how many times you access any particular pieces of data and the unique IP address of your computer. Each time you sign into the PharmGKB website, it will be assumed and documented that you have seen the entire contents of the database on that particular day and time. We are required to keep these records for institutional and federal auditing purposes. These requirements cannot be waived.

By accessing the data on the website, you are agreeing to the following:

  • to have your use of this database tracked,
  • to use the data for research purposes and not with any intent to offer all or any part of the data for sale as a commercial item,
  • to warrant you will not attempt to re-identify the subjects in PharmGKB, and
  • acknowledge that the accuracy of the data in this knowledge base cannot be guaranteed and must be considered when using this data.

Dosing Guidelines

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines Disclaimer: CPIC guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the healthcare provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to persons or property arising out of or related to any use of CPIC's guidelines or for any errors or omissions.
  • All Other Dosing Guidelines: All other dosing guidelines on PharmGKB reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision making and to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variations among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the healthcare provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury to persons or damage to persons or property arising out of or related to any use of dosing guidelines on PharmGKB or for any errors or omissions.

Drug Labels

  • FDA Drug Labels: Please follow all FDA drug label recommendations. Please visit the FDA website for more information.

If you do not agree, you will only have access to the general information pages.

This data is provided "as is", "where is" and without any express or implied warranties, including, but not limited to, any implied warranties of merchantability and/or fitness for a particular purpose. In no event shall Stanford University, nor its agents, employers or representatives be liable for any direct, indirect, incidental, special, exemplary, or consequential damages (including, but not limited to, procurement of substitute goods or services; loss of use, data, or profits; or business interruption) however caused and on any theory of liability, whether in contract, strict liability, or tort (including negligence or otherwise) arising in any way or form out of the use of this data, even if advised of the possibility of such damage.

All users assume the risk and responsibility for the accuracy, completeness or usefulness, or lack thereof, of any information, apparatus, product or process disclosed or that the use hereof would or would not infringe the rights of any other party.


Pathway Reproduction Policy

If you would like to reproduce a PharmGKB pathway diagram, please acknowledge the copyright to PharmGKB and state that permission has been given by PharmGKB and Stanford University. In addition, please check the pathway diagram page to find out whether the pathway has been published in the Pharmacogenetics and Genomics journal. If there is such a citation on the pathway page, please use that. If not, please use the PharmGKB citation below.

Also, please send a brief email to feedback@pharmgkb.org to inform us of which pathway diagram you are using and for what purpose.

Citing the PharmGKB

M. Whirl-Carrillo, E.M. McDonagh, J. M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman and T.E. Klein. "Pharmacogenomics Knowledge for Personalized Medicine" Clinical Pharmacology & Therapeutics (2012) 92(4): 414-417.

Full text.

Website and Other PharmGKB Policies